Patent classifications
C12N2750/14221
Method to homogenize parvovirus B19 in clinical samples
Various aspects of the invention relate to compositions and methods of analyzing blood plasma, blood serum, and manufacturing pools of plasma-derived products wherein an anionic surfactant is added to an aliquot of the blood plasma, blood serum, or manufacturing pool prior to analysis, and the counterion of the anionic surfactant is not sodium ion. The anionic surfactant may be, for example, lauryl sulfate. The counterion of the anionic surfactant may be, for example, lithium ion.
A METHOD TO HOMOGENIZE PARVOVIRUS B19 IN CLINICAL SAMPLES
Various aspects of the invention relate to compositions and methods of analyzing blood plasma, blood serum, and manufacturing pools of plasma-derived products wherein an anionic surfactant is added to an aliquot of the blood plasma, blood serum, or manufacturing pool prior to analysis, and the counterion of the anionic surfactant is not sodium ion. The anionic surfactant may be, for example, lauryl sulfate. The counterion of the anionic surfactant may be, for example, lithium ion.
ERYTHROPARVOVIRUS WITH A MODIFIED CAPSID FOR GENE THERAPY
Disclosed are recombinant virions that have a modified capsid protein or a variant thereof of erythroparvovirus and a nucleic acid that includes a heterologous nucleic acid.